al-Refaie F N, Wonke B, Hoffbrand A V
Department of Haematology, Royal Free Hospital, School of Medicine, London, UK.
Eur J Haematol. 1994 Nov;53(5):298-301. doi: 10.1111/j.1600-0609.1994.tb01323.x.
Agranulocytosis developed in a 63-year-old patient with myelodysplasia 6 weeks after commencing treatment with the oral iron chelator deferiprone (L1, 1,2-dimethyl-3-hydroxypyrid-4-one, CP20) at a daily dose of 79 mg/kg. This was the 3rd case of agranulocytosis (neutrophils 0 x 10(9)/l) in clinical trials of L1 at the Royal Free Hospital. The neutrophil count recovered 7 days after stopping L1 and commencing G-CSF at a dose of 300 micrograms daily. Three other patients with milder degrees of neutropenia (neutrophils < 1.5 x 10(9)/l) have also been observed in our trials. The case histories of these 4 patients are described here; other reported cases of neutropenia or agranulocytosis are reviewed. Based on worldwide long-term clinical trials the incidence of agranulocytosis is about 1.6% and of neutropenia 2%.
一名63岁的骨髓发育异常患者，在开始口服铁螯合剂去铁酮（L1，1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮，CP20）治疗6周后出现粒细胞缺乏症，每日剂量为79 mg/kg。这是皇家自由医院L1临床试验中第3例粒细胞缺乏症（中性粒细胞0×10⁹/L）病例。停用L1并开始每日剂量为300微克的粒细胞集落刺激因子（G-CSF）治疗7天后，中性粒细胞计数恢复。在我们的试验中还观察到另外3例中性粒细胞减少程度较轻（中性粒细胞<1.5×10⁹/L）的患者。这里描述了这4例患者的病史；并对其他报道的中性粒细胞减少或粒细胞缺乏症病例进行了综述。基于全球长期临床试验，粒细胞缺乏症的发生率约为1.6%，中性粒细胞减少症的发生率为2%。
